![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HLA-H |
Gene summary for HLA-H |
![]() |
Gene information | Species | Human | Gene symbol | HLA-H | Gene ID | 3136 |
Gene name | major histocompatibility complex, class I, H (pseudogene) | |
Gene Alias | HLAHP | |
Cytomap | 6p22.1 | |
Gene Type | pseudo | GO ID | GO:0001906 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3136 | HLA-H | HCC1 | Human | Liver | HCC | 1.33e-40 | 4.61e+00 | 0.5336 |
3136 | HLA-H | HCC2 | Human | Liver | HCC | 2.74e-65 | 4.59e+00 | 0.5341 |
3136 | HLA-H | HCC5 | Human | Liver | HCC | 2.32e-26 | 3.77e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001988212 | Liver | HCC | antigen processing and presentation | 65/7958 | 106/18723 | 7.06e-05 | 6.37e-04 | 65 |
GO:000248312 | Liver | HCC | antigen processing and presentation of endogenous peptide antigen | 16/7958 | 19/18723 | 2.37e-04 | 1.79e-03 | 16 |
GO:004800212 | Liver | HCC | antigen processing and presentation of peptide antigen | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
GO:000247411 | Liver | HCC | antigen processing and presentation of peptide antigen via MHC class I | 21/7958 | 28/18723 | 4.94e-04 | 3.23e-03 | 21 |
GO:001988522 | Liver | HCC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 14/7958 | 17/18723 | 9.39e-04 | 5.47e-03 | 14 |
GO:001988312 | Liver | HCC | antigen processing and presentation of endogenous antigen | 18/7958 | 26/18723 | 5.37e-03 | 2.24e-02 | 18 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |